Pro-Dex, Inc. (PDEX) Stock

Pro-Dex, Inc. (PDEX) is a Healthcare stock trading at $66.02 (as of 2026-08-20), with a market capitalization of $210.79M and a trailing P/E of 17.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers, including autoclavable battery-powered and electric surgical drivers and shavers used in orthopedic, thoracic, and craniomaxillofacial applications. It also provides engineering, quality, and regulatory consulting and manufactures and sells rotary air motors for various industries.

Understand Pro-Dex, Inc.: how it makes money

Pro-Dex designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers, and it also sells rotary air motors and provides engineering, quality, and regulatory consulting services.

The company appears to win or lose revenue momentum based on what happens with its largest customer, specifically the balance between legacy product revenue decrease and repair revenue increase.

Business quality (Solid): The business model is clear (powered surgical instruments plus motors and consulting), but the provided quarterly revenue is shown as 0.0B and only one operating KPI is available here, which limits how much can be concluded about trend direction.

Valuation: At 17× earnings, PDEX trades 48% below the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

Broader offering beyond instruments: In addition to powered surgical drivers and shavers for orthopedic, thoracic, and craniomaxillofacial markets, Pro-Dex also provides engineering, quality, and regulatory consulting and manufactures rotary air motors for various industries.
Clear operational focus on largest-customer dynamics: The company tracks legacy product revenue decrease and repair revenue increase for its largest customer, which can help investors understand which customer revenue streams are under pressure or stabilizing.

Bear case

Largest-customer sensitivity: A key tracked operating metric is the legacy product revenue decrease for the largest customer, which implies concentration risk if legacy programs continue to decline.
Limited visibility from the provided quarter: In the latest provided period (2026-03-31), revenue is shown as 0.0B here, making it harder to assess demand and operational momentum from these facts alone.

Valuation — source: SEC EDGAR (first-party)
Price	$66.02
Market Cap	$210.79M
P/E Ratio	17.6
EV / EBITDA	16.2
Price / Book	4.66
Price / Sales	2.82
FCF Yield	3.4%
DCF Value (model)	$45.91
DCF Upside vs Price	-30.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$66.59M
Net Margin	13.5%
Revenue Growth (YoY)	14.6%
EPS Growth (YoY)	23.0%
FCF Growth (YoY)	165.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	8.39 (safe)
Piotroski F-Score	6/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	17.6
Sector P/E (Healthcare)	21.6
Industry P/E (Medical Equipment)	32.9
vs Sector	-18.7%
vs Industry	-46.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($7.49M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Richard Lee Van Kirk Jr.
Employees	146
Country	US
IPO Date	1986-08-07

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.